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Abstract
Brugada syndrome is a congenital electrical disorder characterised by the appearance of dis-
tinctive QRST-T patterns in the right precordial leads and an increased risk of sudden death
(SCD) in young healthy adults. Although chamber enlargement is not apparent in most cases,
autopsy and histological investigations have revealed structural abnormalities. The typical
Brugada ECG manifestation is often concealed and may be revealed by Class IC anti-arrhyth-
mic agents with the effect of blocking the fast component of sodium channel currents. The
syndrome may also be unmasked or precipitated by a febrile state, vagotonic agents, a-adrener-
gic agonists, b-adrenergic blockers, tricyclic or tetracyclic antidepressants, a combination of
glucose and insulin and hypokalaemia, as well as by alcohol and cocaine toxicity. Since the
typical Brugada ECG pattern can be normalised by Class IA agents to block transient outward
currents (Ito) or by isoproterenol and cilostazol to boost calcium channel currents, they have
been considered pharmacological therapies aimed at rebalancing the ion channel currents
during cardiac depolarisation and repolarisation. Case studies by intra-cardiac mapping-
guided ablation in the right ventricular outflow tract and Purkinje network have shown
evidence of eliminating the substrate of ventricular tachycardia/fibrillation (VT/VF) in
Brugada syndrome, which may be used as an adjunct to device therapy to abort electrical
storms. At present the most effective therapy to prevent sudden cardiac death in Brugada
syndrome is an implantable cardioverter defibrillator. (Cardiol J 2007; 14: 97–106)
Key words: Brugada syndrome, quinidine, isoproterenol, implantable cardioverter
defibrillator, radiofrequency ablation
Introduction
The literature to date has shown some benefit
in treating Brugada syndrome in special circum-
stances with Ito channel-inhibiting drugs in phase 1
of action potential, and with drugs that stimulate
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the slow calcium channel in phase 2. In clinical prac-
tice quinidine and isoproterenol are the drugs used.
We believe that the isolated use of quinidine in
symptomatic Brugada syndrome requires a great-
er number of evidence-based medical cases. Quini-
dine is indicated in association with an implantable
cardioverter defibrillator (ICD) to decrease the
number of shocks that the device should apply. Low-
dose quinidine has potential as an adjunctive ther-
apy for Brugada syndrome patients with frequent
ICD shocks. Additionally, quinidine is indicated in
oral administration in electrical storms in associa-
tion with the treatment of choice. These are rare
and ominous events with a high rate of lethality.
Isoproterenol should be immediately infused in as-
sociation with cardiopulmonary bypass and gener-
al anaesthesia. If this procedure proves to be insuf-
ficient, oral quinidine should be administered. In the
absence of response to the above-mentioned steps,
radiofrequency ablation should be attempted. Final-
ly, in the face of sequential failure of these resourc-
es, it is possible to apply, exceptionally and as
a heroic measure, orthotopic transplantation, which
has been recorded only once in the literature on
Brugada syndrome.
The pharmacological alternative is of great so-
cial interest in poor third-world countries and in de-
veloping countries, where cardioverter defibrilla-
tors are unaffordable and where very small infants
are involved, making implantation technically im-
possible.
Infusion of the b-adrenergic stimulant agent
isoproterenol is the treatment of choice in an elec-
trical storm, because it boosts the L-type calcium
current [I (Ca-L)], an adjunct to aortocoronary by-
pass and general anaesthesia. The same mechanism
of action has been proposed for a possible benefi-
cial effect of cilostazol.
For symptomatic carriers of the syndrome with
a history of syncope or aborted sudden death (sec-
ondary prevention), the implantation of ICDs is the
management of choice. We believe that associated
oral quinidine in low doses is indicated.
Some groups of researchers have, in a small
number of cases, demonstrated that arrhythmic
events may be eliminated using mapping and ven-
tricular fibrillation ablation associated with Bruga-
da syndrome. In spite of the promise of this form of
management, it is considered to be an experimen-
tal procedure, as there is no proof of its safety in
the follow-up in a significant number of patients.
Currently the procedure is justified in an electrical
storm after failure of an association of isoprotere-
nol/aortocoronary bypass/general anaesthesia.
The following are analysed successively: the
value of drugs, implantable cardioverter defibrilla-
tors (ICDs), treatment with implantable pacemak-
ers (IP) in Brugada syndrome (BrS) and allelic dis-
eases, therapy of an electrical storm (ES) and map-
ping and ablation of ventricular fibrillation (VF)
associated with BrS.
The value of drugs agents that
block the Ito channel
Quinidine
Quinidine is a Class IA anti-arrhythmic drug,
the isomer of the quinine found in the bark of the
cinchona tree. The drug affects depolarisation and
repolarisation by blocking the Na+ and K+ channels
respectively. The rapid Na+ channel block accounts
for its greater effect on depressing Vmax at faster
rates. In BrS it is used for its property of blocking
the Ito channel and thus restoring electrical homo-
geneity across the ventricular myocardial wall, and
also in order to eliminate arrhythmias by phase
2 re-entry. Quinidine, by virtue of its action in block-
ing Ito, has been proposed as adjunctive therapy, with
an ICD as backup. Additionally the drug has a ben-
eficial vagolytic effect, which occurs through mus-
carinic (M2) receptor block. The channel blocks by
means of drugs and their pharmacokinetic effect on
ECG and electrophysiological intervals are summa-
rised in Table 1.
In 1987 Imaizumi and Giles [1] showed that qui-
nidine induced inhibition of Ito in the cardiac mus-
cle. Extracellular application of quinidine reduced
whole-cell cloned Ito amplitude in a concentration-
dependent manner [2].
Research from the Masonic Medical Research
Laboratory has suggested a new pharmacological
approach to therapy using „transient outward cur-
rent” blockers. This pharmacological alternative
may be critically important in many parts of the
world where ICDs are not affordable [3]. Addition-
ally, this is particularly important because BrS pa-
tients are at risk of sudden cardiac death (SCD) from
the age of 6 months [4], and an ICD implant is not
feasible in very young symptomatic children [5].
Belhanssen et al. [6] performed an electrophys-
iological (EP) study in 34 consecutive patients who
had IVF with (n = 5) or without (n = 29) BrS. All
patients with inducible sustained polymorphic ventricu-
lar tachycardia/ventricular fibrillation (SPVT/VF)
underwent repeated EP evaluation after oral adminis-
tration of quinidine. Patients rendered non-inducible
received this therapy on a long-term basis. SPVT/VF
was induced in 27 (79.4%) patients at baseline studies.
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Quinidine effectively prevented induction of SPVT/VF
in 26 (96%) patients. Of the 23 patients treated with
these medications no patient died or had a SPVT
during a mean follow-up period of 9.1 ± 5.6 years
(7 to 20 years in 15 patients). Two deaths occurred
in patients without inducible SPVT/VF at baseline
studies who had been treated empirically. This re-
sult suggests that EP-guided therapy with quinidine
is a reasonable, safe and effective approach for the
long-term management of patients.
Publications have shown a decrease or disap-
pearance of ST elevation in right precordial leads
with administration of quinidine by decreasing the
initial outflow of potassium through the Ito channel
[7, 8]. The drug also suppresses all ambient unifo-
cal premature ventricular contractions (PVCs) and
induction of VF on programmed electrical stimula-
tion. Additionally, it could improve repolarisation as
a result of its vagolytic effect (M2 muscarinic recep-
tor block) and the exacerbation of reflex sympathet-
ic tone. Hydroquinidine therapy prevented VT/VF
inducibility in 76% of asymptomatic patients with
BrS inducible arrhythmia, as well as VT/VF recur-
rence in all BrS patients with multiple ICD shocks.
These data suggest that preventive treatment with
this drug may be an alternative strategy to ICD place-
ment in asymptomatic patients with BrS and induc-
ible arrhythmia [9].
At a dose of oral 1000 mg to 1500 mg/day (300 mg
every 6 h) [10] quinidine bisulphate can be success-
ful in the suppression of an ES.
The management of patients with BrS is still
far from well defined. Interestingly, in some reports
hydroquinidine has been shown to reduce the inci-
dence of spontaneous ventricular tachycardia in the
follow-up as well as the frequency of VT/VF induced
in the EP lab. Yet prophylactic ICD implantation re-
mains the treatment of choice in symptomatic and
inducible patients [11].
For ES quinidine could be effective in halt-
ing new ominous events [12]. Quinidine may be
regarded as an adjunctive therapy for patients at
higher risk and may reduce the number of cases
of ICD shock in patients with multiple recurrenc-
es [13].
The electrical storm is a rare but malignant and
potentially lethal event. Isoproterenol should im-
mediately be infused in association with bypass and
general anaesthesia, while oral quinidine should be
further administered when these procedures are
not effective. In the event of the failure of these
therapeutic options ablation of the triggering ven-
tricular ectopies should be attempted [14].
Recently Probst et al. [15] have attempted suc-
cessfully to use hydroquinidine in the 16-month
follow-up of a 3-year-old child, a carrier of BrS, who
had had repetitive episodes of monomorphic ven-
tricular tachycardia.
Watanabe et al.  [16] showed in a study con-
ducted in 8 BrS carrier patients that the beneficial
effect of quinidine that decreases ST-segment ele-
vation in the right precordial leads is more marked
in those patients with a greater degree of elevation
in baseline ECG and that the drug may possibly in-
crease ST-segment elevation in some BrS carrier
patients (a paradoxical effect).
Table 1. Channels and receptors blocked by
quinidine, pharmacokinetics of quinidine and
effect on ECG and electrophysiological intervals
of quinidine
Channels and receptors blocked by quinidine
Fast Na+ current: phase 0 of action potentials
Ito1 channel or transient outward current: phase 1
Inward rectifier IK1
Delayed rectifier: IKS, IKR and IKUR: phase 3 of action
potentials
IKATP or adenosine triphosphate ATP sensitive
potassium channel
IK-Ach
a1 and a2 adrenergic receptors: can cause orthostatic
hypotension and reflex sinus tachycardia
M2 muscarinic receptor: vagolytic effect
Pharmacokinetics of quinidine
Bioavailability: 70–85%
Protein binding: 70–95% with a1 glycoprotein
Time-to-peak concentration: 1–4 h
Elimination T1/2: 6 h or 8 h
Therapeutic range: 2–5 mg/ml
Elimination route: hepatic through the cytochrome
P450 system
Effects on ECG and electrophysiological intervals
of quinidine







Atrium effective refractory period: >+
Atrioventricular node effective refractory period: >+
His-Purkinje system effective refractory period: >+
Ventricle effective refractory period: >+
Accessory pathway effective refractory period: >+
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Tedisamil
Tedisamil dihydrochloride is an experimental
drug that exerts anti-ischaemic and anti-arrhythmic
effects by the blockade of the cellular cardiac repo-
larisation K+ currents as well as of multiple neuro-
nal and vascular K+ currents (Ito, Ik, and K+ATP).
Ito blockers may be more potent than quinidine be-
cause of the lack of the relatively strong inward
current blocking actions of quinidine. The develop-
ment of a cardioselective and Ito-specific blocker is
necessary in addition to the limited therapeutic ar-
mamentarium currently available to combat this
disease. Appropriate clinical trials are needed to
establish the effectiveness of all the above pharma-
cological agents. Cardioselective and Ito-specific
blockers are not currently available commercially.
Tedisamil is a bradycardiac agent [17] that pro-
longs the QT interval of ECG. Drug-induced pro-
longation of the interval between the peak and end
of the T wave (QTa-e) is reverse rate-dependent
and is associated with the occurrence of a torsades
de pointes rate and potassium. Tedisamil might be
expected to have pro-arrhythmic actions similar to
Class III anti-arrhythmic drugs [18].
Cilostazol
Tsuchiya et al. [19] reported a case of 67-year-
-old man with BrS, in whom daily episodes of VF oc-
curred early in the morning for four consecutive days.
The episodes of VF were completely prevented by an
oral administration of cilostazol (Cebralat® Libbs, Ple-
tal®). However, a recent publication has shown cilosta-
zol to be ineffective in BrS carrier patients [20].
The drug is a quinolinone derivative that inhib-
its cellular phosphodiesterase type III (PDE III in-
hibitor). This effect was confirmed by the on-and-
off challenge test, in which discontinuation of the
drug resulted in recurrence of VF and resumption
of the drug again prevented VF. This effect may be
related to the suppression of Ito activity secondary
to the increase in heart rate and/or to an increase
in L-type calcium current [I (Ca)] because of an el-
evation of intracellular cyclic AMP concentration via
inhibition of phosphodiesterase activity. The drug
might have an anti-VF potential in patients with
BrS. Concomitant administration of quinidine with
a single dose of cilostazol 100 mg did not alter
cilostazol pharmacokinetics. The two drugs in as-
sociation in patients with BrS could theoretically
have more strength in inhibiting the Ito channel and
eliminating arrhythmias by phase 2 re-entry.
Oral denopamine, atropine or cilostazol all in-
crease ICa2+-L, and for this reason may be effective
in reducing episodes of VF.
Cilostazol is indicated in clinical practice for
intermittent claudication, because it affects both
vascular beds and cardiovascular function. It pro-
duces non-homogeneous dilation of the vascular
beds, with greater dilation in the femoral beds than
in the vertebral, carotid, or superior mesenteric
arteries. The renal arteries have not been respon-
sive to the effects of cilostazol.
Adrenergic agents
The infusion of isoproterenol, a b-adrenergic
stimulant, strongly augments L-type calcium cur-
rent [I(Ca-L)] and is the first choice for suppress-
ing ES associated with BrS [21]. Isoproterenol can
improve ventricular repolarisation, decreases ele-
vation of the J point and ST segment and normalis-
es ECG in BrS [22]. The administration of isoprot-
erenol associated with general anaesthesia and car-
diopulmonary “bypass” is effective in diminishing
ST-elevation in the right precordial leads, disap-
pearance of short-coupled premature beats and re-
moving ES crises of VF [23–28].
ST elevation in V1-V3 was decreased by 1 mm
or more after isoproterenol infusion in 8 of 11 cas-
es of BrS. In a ventricular activation isochronal map
of the body surface delayed conduction was noted
on the upper anterior chest in 11 and on the anteri-
or left chest in 2. Delayed conduction areas were
decreased by isoproterenol. A QRST isointegral
map showed normal findings in baseline with min-
imal changes after isoproterenol. An activation re-
covery interval (ARI) isochronal map was reduced
by isoproterenol. Activation recovery interval dis-
persion (ARI-d), defined as the difference between
the maximum and minimum values of the ARI,
was decreased after isoproterenol [29]. The late po-
tential from signal-averaged electrocardiography
during isoproterenol infusion in patients with BrS
was tested by Takagi et al. [30]. The subjects were
11 patients with BrS and 6 healthy individuals. In
all subjects the total filtered QRS duration (fQRS),
the root mean square voltage of the 40 ms terminal
portion of the QRS [RMS(40)], of the low amplitude
electrical potential component (40 mV) of the ter-
minal portion of the QRS [LAS(40)] and the dura-
tion of the fQRS-LAS(40) difference were compared
when isoproterenol was prescribed and when it was
not. During isoproterenol infusion an unusual re-
sponse, which resulted in LAS(40) prolongation,
was observed in the patients with BrS. With isopro-
terenol infusion the fQRS remained unchanged, but
the RMS(40) and the fQRS-LAS(40) decreased. Con-
sequently another 3 patients with a positive late po-
tential were diagnosed using the accepted standard
101
Andrés Ricardo Pérez Riera et al., The management of Brugada syndrome patients
www.cardiologyjournal.org
because of the administration of isoproterenol. The
authors believe that the low-amplitude component
was unmasked by shortening of the high-amplitude
component. In patients with BrS the presence of
a conduction delay in the right ventricle may be re-
lated to the occurrence of VF.
Dobutamine has been used as a pharmacologi-
cal test in the identification of patients with risk,
asymptomatic carriers or relatives of individuals
with BrS. The test, known as the “Ajmaline and
Dobutamine Test” consists of the administration of
ajmaline, and later, if the patient develops the type-1
Brugada ECG pattern, he or she will receive dobu-
tamine. If the electrocardiographic alterations disap-
pear, the subject is considered test-positive, thus
providing a basis for indicating EPS [31].
During high cardiac frequencies, the Ito channel
becomes less prominent, which explains the de-
crease in ST-segment elevation and reduced ven-
tricular arrhythmias at higher heart rates. This is
a basis for indicating overdrive pacing in the preven-
tion of VF in BrS [32].
Amiodarone
Anti-arrhythmic drugs such as amiodarone and
b-blockers do not prevent SCD in symptomatic or
asymptomatic individuals [33–35].
There are references to the efficacy of intrave-
nous amiodarone in ES. Some researchers consider
the use of an ICD plus amiodarone to be the treat-
ment of choice. Adjunctive treatment with amiodar-
one reduced J-wave amplitude, preventing VF and
decreasing the number of ICD shocks [36]. On the
other hand, we do not consider amiodarone to be ef-
fective, the best association with ICD being quinidine.
Chronic amiodarone reduces the transmural
dispersion of repolarisation in the heart as a result
of aminopyridine duration prolongation in both the
epicardium and endocardium, but there is less of
a prolongation in the M region [37, 38]. Amiodar-
one prevents torsade de pointes in long QT syndrome
(LQTS) by suppression of the trigger responsible
for initiation or elimination of the substrate for re-
entry, via a reduction in the transmural dispersion
of repolarisation. Torsade de pointes is a form of pol-
ymorphic VT in the setting of a prolonged QT in-
terval. Any drug, such as amiodarone, that prolongs
repolarisation and hence the QT interval may cause
torsade de pointes.
Sotalol
Sotalol may be of therapeutic benefit in patients
with BrS. Glatter et al. [39] described a case of
a 53-year-old man with recurrent syncopal events
and a malignant family history, who was treated for
13 years with sotalol drug therapy with no further
occurrence of BrS symptoms. Genetic testing re-
vealed that he carried a BrS sodium channel SCN5A
mutation (4189delT).
How is the significant clinical benefit obtained
with sotalol in a patient carrier of BrS to be ex-
plained? In BrS several channels are affected:
— Primarily, the fast Na+ one [40].
— Secondarily, the Ito1; ITOA; ITOF; the ITO-FAST chan-
nel; the transient outward current, 4-aminopy-
ridine (4-AP) sensitive, calcium-independent
transient outward current or voltage-operated
potassium channel. There are different densi-
ties of the Ito channel in ventricular wall thick-
ness with many in the epicardium and few or
none in the endocardium. This is the reason for
the pronounced notch in phase 1, which is in
the epicardium only and minimal or absent in
the endocardium. Additionally, an idiopathic J
wave has a different sensitivity to ischaemia
and drugs in the different regions of ventricu-
lar wall thickness. Thus in the epicardium AP
duration is more sensitive to K+ concentrations
and HR variations [3, 41].
— Ca2+ voltage-dependent channel, the independ-
ent transient outward current or ICa2+-L channel.
The inhibition of this channel and IK-ATP activa-
tion significantly contributes in BrS to trans-
mural dispersion of repolarisation, in ST-seg-
ment elevation and also to re-entry onset in
phase 2 [42].
— Ik-ATP channel or time-independent K+ current,
activated by the fall in ATP intracellular con-
centration, ischaemia and hypoxia [43, 44] and
inhibited by sulphonylureas such as glybencla-
mide [45]. Activation of an ATP-dependent
potassium current can produce a marked dis-
persion of repolarisation and refractoriness in
the epicardium as well as between the epicar-
dium and the endocardium, leading to the de-
velopment of extrasystolic activity via a mech-
anism referred to by Antzelevitch’s team as
phase 2 re-entry. The blockade of the transient
outward current and/or the ATP-regulated po-
tassium channels may be useful anti-arrhyth-
mic interventions under ischaemic or ”ATP
depleted” conditions [46–48].
Sotalol is a drug made up by the racemic mix-
ture of two isomers, D and L. The first is a b-block-
ing (Class II anti-arrhythmic agent) non-cardiose-
lective component, without intrinsic sympathomi-
metic activity or membrane stabiliser. The L isomer
has class III properties by blocking the fast outward K+
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or IKUR channels at the end of phase 2 and phase 3 of
aminopyridine. Thus the IKR channel is the one affect-
ed in type 2 congenital LQTS (LQT2 or HERG). The
drug does not affect the Ito channel or the IKUR channel.
Many pharmacodynamic effects of sotalol re-
main unexplained. If the drug does not act on any
of the affected channels in BrS, how is the clear clin-
ical benefit to be explained that has been obtained
with the use of this drug in keeping a 53-year-old
patient free of symptoms for 13 years, a patient who
had previously been highly symptomatic with re-
current syncopes and positive genetic testing for
the mutation (4189delT) in the SCN5A gene (true
Brugada disease)? We conjecture that the delay in
repolarisation caused by the drug subsequent to
inhibition of the fast outward K+ current in the end
of phases 2 and 3 of aminopyridine in turn causes
a delay in the activation of the slow Ca2+ inward chan-
nels (ICa2+-L). The inhibition of this channel contributes
to transmural dispersion of repolarisation and ST-seg-
ment elevation. Therefore the D isomer of sotalol, by
causing a delay in the inactivation of the slow Ca2+
inward channel (ICa2+-L), fosters a decrease in ST-seg-
ment elevation, thus preventing functional re-entry
being triggered in phase 2, which is the basis for poly-
morphic ventricular tachycardia/ventricular fibril-
lation bursts. Additionally, the absolute increase in in-
tracellular Ca2+ is responsible for positive inotropism
counterbalancing the negative inotropic and b-blocking
actions, for which the L isomer is responsible.
Implantable cardioverter-defibrillator
therapy in Brugada syndrome
The onset of VT/VF in BrS patients is the pri-
mary cause of SCD and thus ICD is currently the
only proven effective treatment, although inappro-
priate shocks frequently result.
There are two circumstances which constitute
indications for this.
Secondary prevention
ICDs are indicated in patients who have previ-
ously experienced syncope or who have been resus-
citated from SCD. The Unexplained Cardiac Arrest
Registry of Europe (UCARE) has shown that patients
with sustained VT/VF run a high risk of recurrence.
ICD implantation is then the treatment of choice [49].
Primary prevention: asymptomatic patients
at high risk of SCD without prior arrhythmias
Only 1% to 5% of patients survive an out-of-
-hospital cardiac arrest, which emphasises the need
for primary prevention of SCD [50].
Data from Brugada series indicate that the
asymptomatic BrS patients at highest risk are males
with inducible VT/VF and a spontaneously elevat-
ed ST segment (Type 1 ECG pattern). However,
from the Priori and Eckardt series EPS is unnec-
essary and has no place in risk stratification in these
patients. These studies suggest that asymptomat-
ic patients with Brugada-type ECG who have no
family history of SCD have a relatively benign clin-
ical course [51]. Until more specific data are availa-
ble the recommendation with respect to patients
who manifest a spontaneous Type 1 ECG only af-
ter placement of the right precordial leads in a su-
perior position is to treat them no differently from
patients exhibiting a spontaneous Type 1 ECG with
the leads in the standard positions.
The low incidence of ICD used in primary preven-
tion patients serves to emphasise that efforts should
be made to develop better instruments for risk strati-
fication [52]. Asymptomatic patients who have no family
history and who develop a Type 1 ECG only after sodi-
um channel blockade should be closely followed up.
High-risk patients with LQTS, short QT syn-
drome (SQTS), hypertrophic cardiomyopathy, ar-
rhythmogenic right ventricular cardiomyopathy and
BrS are candidates for prophylactic ICD implanta-
tion, although questions remain regarding what
constitutes high risk in these patient populations.
The death rate is 0% in patients who have received
ICD treatment. However, owing to the risks in-
volved, ICD implantation in the increasingly young
patient population is a very difficult clinical decision.
New evidence suggests that an ICD may be effec-
tive for primary prevention of sudden death. The
high instrumental cost and the potentially large
number of candidates will have a significant impact
on hospital budgets [53].
Treatment with implantable pacemakers
in Brugada syndrome and allelic diseases
Mutations in SCN5A lead to a large spectrum
of phenotypes, including LQT3, BrS, mixed forms
and isolated progressive cardiac conduction defects
(Lenègre disease).
Because Itoo becomes less prominent at a fast-
er rate, increased heart rate is associated with de-
creased ST-segment elevation in ECG and proba-
bly a decreased incidence of VT/VF. There is one
report on the prevention of VF in a man with BrS
by overdrive pacing from his dual chamber ICD [32].
Patients with isolated progressive cardiac con-
duction defect and syncope episode require pace-
maker implantation [54, 55].
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Successful treatment appears to be permanent
with pacemakers, which stop the heart from slow-
ing excessively, although this may not prevent ven-
tricular arrhythmias. Therefore additional medical
treatment with tablets or even an ICD may be ap-
propriate.
In the LQT3 variant it has been reported that
cardiac pacing in has a beneficial effect. Cardiac
pacing is clearly indicated in patients with LQTS
with atrioventricular block and whenever there is
evidence of pause-dependent malignant arrhythmi-
as. The pacemakers must always be used in asso-
ciation with b-blocking therapy. Pacemakers that
control the heart rate have been used successfully,
as have ICDs. These are similar to pacemakers,
except they are also able to cause a shock to the
heart when a rhythm disturbance occurs that might
be life threatening. In addition to these measures,
we advise patients with LQTS to avoid excessive
exercise or strenuous athletic activities.
The implantation of a pacemaker has turned out
to be an effective prevention for SCD in the LQT3
variant. These facts indicate that the mechanism of
lethal tachyarrhythmias may possibly be associat-
ed with bradycardia in some cases of BrS.
Pacemaker implantation has proved to be ex-
tremely effective in patients with the 1795InsD
mutation in SCN5A, which manifests combined
Brugada and LQTSy phenotypes (mixed forms). We
have no data that might exclude further study of the
potential value of pacemaker therapy.
Therapy of an electrical storm
in Brugada syndrome
Electrical storms are recurrent multiple epi-
sodes of VF or VT, 20 or more episodes per day or
4 or more per hour.
Isoproterenol improves ventricular repolarisa-
tion, and decreases elevation of the J point and ST
segment and can even normalise the ECG tracings
in BrS. This drug has therefore been used in treating
the so-called “electrical storm”. Isoproterenol is in-
dicated in ES in association with general anaesthesia
and cardiopulmonary “bypass”. There are referenc-
es to suppression of ES by oral quinidine [56, 57].
If isoproterenol associated with bypass and
general anaesthesia and oral quinidine are ineffec-
tive in suppressing ES, radiofrequency ablation
should be attempted. Finally, cardiac transplanta-
tion may be the last option for BrS patients with
frequent ES who are unresponsive to all available
treatment [58]. There is one case reported in the
literature of a patient with BrS who required heart
transplantation to control multiple ES. This took the
form of recurrent ES treated with isoproterenol
associated with general anaesthesia and cardiopul-
monary “bypass” that did not respond and which was
treated with heart orthotopic transplantation [59].
Mapping and ablation of
ventricular fibrillation associated
with Brugada syndrome
Until recently, the management of patients who
have survived SCD has focused on treating the con-
sequences by implantation of an ICD. However,
such therapy remains restricted in many countries
and is associated with a prohibitive cost to the com-
munity. The high instrumental cost and the poten-
tially large number of candidates would have a sig-
nificant impact on hospital budgets [60] and may be
a cause of significant morbidity in patients with fre-
quent episodes of ES or arrhythmia. Recurrent VT
or VF followed by frequent ICD shocks might thus
put patients in a painful situation.
Evidence emerging from the study of fibrilla-
tion both in the atria and the ventricle suggests an
important role for triggers arising from the Purkinje
network or the right ventricular outflow tract in the
initiation of VF. Initial experience in patients with
idiopathic ventricular fibrillation, and even those
with VF associated with LQTS, BrS and genuine Id-
iopathic VF, suggests that long-term suppression
of recurrent VF may be feasible by the elimination
of these triggers. With the development of new
mapping and ablation technologies and greater phy-
sician experience catheter ablation of VF, with the
ultimate aim of curing such patients at risk of SCD,
may not be an unrealistic goal in the future [61, 62].
Haissaguerre et al. [63] localised the earliest
endocardial activity by mapping and by focal radiof-
requency ablation of polymorphic ventricular tachy-
cardia/ventricular fibrillation in three patients with
BrS. The authors conclude that triggers from the
Purkinje arborisation or the right ventricular out-
flow tract have a crucial role in initiating VF asso-
ciated with BrS and LQTS. These can be eliminat-
ed by focal radiofrequency ablation.
In a highly symptomatic 18-year-old-male with
BrS frequent episodes of VF, fast polymorphic ven-
tricular tachycardia and fast sustained monomorphic
ventricular tachycardia were observed. The episodes
were classified as VT or VF and as a consequence
received appropriate therapies with the ICD. Precip-
itating ventricular premature contractions (VPCs)
stored in the ICD memory and on the ECG exhibit-
ed the same morphology as frequent isolated VPCs.
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During the electrophysiological study right and left
atrial tachycardia with one-to-one atrioventricular
conduction were induced and successfully ablated. VF
was ablated using the same non-contact mapping sys-
tem-triggering VPCs from right ventricular outflow
tract [64].
Yu at al. [65] presented a case of recurrent syn-
cope diagnosed as recurrent VF by an implanted
loop recorder. The VF was eliminated by radiofre-
quency ablation of the triggering ventricular pre-
mature complexes.
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